Literature DB >> 15108100

Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy.

Joel B Epstein1, Edmond L Truelove, Kimberly Hanson-Huggins, Lloyd A Mancl, Alice Chen, Oliver W Press, Stephen H Petersdorf, Thomas R Fritsche, Joshua D Epstein.   

Abstract

PURPOSE: The effectiveness of amphotericin B oral suspension versus nystatin oral suspension for the prevention of oral colonization by Candida in hematopoietic cell transplant (HCT) patients was examined.
METHODS: Prior to hematopoietic cell infusion, 40 patients receiving systemic fluconazole for prophylaxis were randomized to receive either amphotericin B oral suspension or nystatin oral suspension, q.i.d. The study continued to day 21 or until the patient was discharge from the hospital or withdrawn from the study. Oral examinations were conducted twice weekly, and adverse events and compliance were recorded. Cultures were taken for quantitative counts and species identification. Candida isolates were assessed for resistance to the oral antifungal agents. Blood was collected for assessment of amphotericin B levels. RESULTS AND DISCUSSION: Ulcerative mucositis occurred in 84.6% of patients undergoing HCT, and no correlation was observed between the severity of mucositis and the presence of oral Candida and the severity of mucositis. Systemic and topical antifungal treatment resulted in a decrease in the number of colonized patients (54.8% before treatment; 23.1% during treatment); however, oral colonization was not eliminated. Tolerability of the oral rinse products was limited, with greater noncompliance in the amphotericin B than the nystatin group. Reports of altered taste appeared to be greater in the amphotericin B group. Minimal absorption of amphotericin B was seen following oral rinsing (serum levels 0.12-0.50 microg/ml), and no consistent changes in organism susceptibility to polyenes were seen. The results suggest that topical antifungal rinses may further control oropharyngeal colonization by Candida in patients on systemic antifungals receiving HCT, but the effect is limited by tolerability and reformulation and should be considered in order to increase compliance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15108100     DOI: 10.1007/s00520-004-0634-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  49 in total

1.  Fungal infection in acute leukemia.

Authors:  H S Mirsky; J Cuttner
Journal:  Cancer       Date:  1972-08       Impact factor: 6.860

2.  A long-term prospective clinical study of oral complications during conventional chemotherapy for acute leukemia.

Authors:  A P Barrett
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1987-03

3.  Absorption of orally administered amphotericin B lozenges.

Authors:  M S Ching; K Raymond; R W Bury; M L Mashford; D J Morgan
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

4.  Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS.

Authors:  S L Newman; T P Flanigan; A Fisher; M G Rinaldi; M Stein; K Vigilante
Journal:  Clin Infect Dis       Date:  1994-10       Impact factor: 9.079

5.  Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients.

Authors:  I M Hann; H G Prentice; R Corringham; H A Blacklock; M Keaney; M Shannon; P Noone; E Gascoigne; J Fox; E Boesen; M Szawatkowski; A V Hoffbrand
Journal:  Lancet       Date:  1982-04-10       Impact factor: 79.321

6.  Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B.

Authors:  F Menichetti; A Del Favero; P Martino; G Bucaneve; A Micozzi; D D'Antonio; P Ricci; M Carotenuto; V Liso; A M Nosari; T Barbui; G Fasola; F Mandelli
Journal:  Ann Intern Med       Date:  1994-06-01       Impact factor: 25.391

7.  Oral candidiasis in hematopoietic cell transplantation patients: an outcome-based analysis.

Authors:  Joel B Epstein; Pamela J Hancock; Stephen Nantel
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2003-08

8.  Treatment and prevention of oropharyngeal candidiasis.

Authors:  R Quintiliani; N J Owens; R A Quercia; J J Klimek; C H Nightingale
Journal:  Am J Med       Date:  1984-10-30       Impact factor: 4.965

9.  Amphotericin B-resistant yeast infection in severely immunocompromised patients.

Authors:  W G Powderly; G S Kobayashi; G P Herzig; G Medoff
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

10.  Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection.

Authors:  M Ruhnke; A Eigler; I Tennagen; B Geiseler; E Engelmann; M Trautmann
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

View more
  7 in total

Review 1.  Interventions for preventing oral candidiasis for patients with cancer receiving treatment.

Authors:  J E Clarkson; H V Worthington; O B Eden
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 2.  Candidiasis (oropharyngeal).

Authors:  Caroline L Pankhurst
Journal:  BMJ Clin Evid       Date:  2013-11-08

Review 3.  How I treat refractory chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Adela R Cardones; Keith M Sullivan
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

Review 4.  Candidiasis (oropharyngeal).

Authors:  Caroline L Pankhurst
Journal:  BMJ Clin Evid       Date:  2012-02-20

Review 5.  Nystatin prophylaxis and treatment in severely immunodepressed patients.

Authors:  Peter C Gøtzsche; Helle Krogh Johansen
Journal:  Cochrane Database Syst Rev       Date:  2014-09-04

Review 6.  Candidiasis (oropharyngeal).

Authors:  Caroline L Pankhurst
Journal:  BMJ Clin Evid       Date:  2009-03-18

7.  Factors Affecting the Incidence and Severity of Oral Mucositis Following Hematopoietic Stem Cell Transplantation.

Authors:  Maryam Valeh; Mona Kargar; Ava Mansouri; Hosein Kamranzadeh; Kheirollah Gholami; Kazem Heidari; Moluk Hajibabaei
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-04-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.